Promising cancer drug trial pulled before it even started
NCT ID NCT06297629
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial aimed to test the drug ASTX727 (Inqovi) alone or with donor immune cells in people with blood cancers who had a stem cell transplant. The goal was to see if it could control cancer that remained or came back. However, the study was withdrawn before enrolling any patients, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASTX727 (oral decitabine/cedazuridine) and donor lymphocyte infusion
What this could lead to
If it worked, this could offer a new way to control blood cancers that return or persist after a stem cell transplant.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. It is unclear if the treatment would be safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States